Despite huge research efforts towards the molecular characterisation of breast cancer over the last decades, treatment decisions are still mainly based on this limited set of biomarkers (HR, HER2), and therefore treatment strategies remain insufficiently targeted. This evidence concerns the gene ERBB2 and breast cancer.